Item 2.02 Results of Operations and Financial Condition.
OnMay 5, 2023 ,Pardes Biosciences, Inc. (the Company) issued a press release announcing its financial results for the quarter endedMarch 31, 2023 . A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company announces material information to its investors using filings with theSecurities and Exchange Commission and the Company's website at https://ir.pardesbio.com, as well as press releases, public conference calls, presentations and webcasts. Therefore, the Company encourages investors, the media and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information. Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release by the Company datedMay 5, 2023 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
--------------------------------------------------------------------------------
© Edgar Online, source